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Abstract
Background and Purpose—Medical and endovascular treatment options for stroke prevention
in patients with symptomatic intracranial stenosis have evolved over the past several decades, but
the impact of 2 major multi-center randomized stroke prevention trials on physician practices has
not been studied. We sought to determine changes in US physician treatment choices for patients
with intracranial atherosclerotic stenosis (ICAS) following 2 NIH-funded clinical trials that
studied medical therapies (antithrombotic agents and risk factor control) and percutaneous
transluminal angioplasty and stenting (PTAS).
Methods—Anonymous surveys on treatment practices in patients with ICAS were sent to
physicians at 3 time points: before publication of the NIH-funded Warfarin-Aspirin Symptomatic
Intracranial Disease (WASID) Trial (pre-WASID, 2004); 1 year after WASID publication (post-
WASID, 2006); and 1 year after the publication of the NIH-funded Stenting and Aggressive
Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) Trial
(post-SAMMPRIS, 2012). Neurologists were invited to participate in the pre-WASID survey
(n=525). Neurologist and Neurointerventionists were invited to participate in the post-WASID
(n=598) and post-SAMMPRIS (n= 2080) survey. The 3 surveys were conducted using web-based
survey tools delivered by email, and a fax-based response form delivered by email and
conventional mail. Data were analyzed using the chi-square test.
Results—Pre-WASID, there was equipoise between warfarin and aspirin for stroke prevention in
patients with ICAS. The number of respondents who recommended antiplatelet treatment for
ICAS increased across all 3 surveys for both anterior circulation (pre-WASID=44%, post-
WASID=85%, post-SAMMPRIS=94%) and posterior circulation (pre-WASID=36%, post-
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WASID=74%, post-SAMMPRIS=83%). The antiplatelet agent most commonly recommended
post-WASID was aspirin, but post-SAMMPRIS it was the combination of aspirin and clopidogrel.
The percentage of neurologists who recommended PTAS in > 25% of ICAS patients increased
slightly from pre-WASID (8%) to post-WASID (12%), but then decreased again post-
SAMMPRIS (6%). The percentage of neurointerventionists who recommended PTAS in > 25% of
ICAS patients decreased from post-WASID (49%) to post-SAMMPRIS (17%).
Conclusions—The surveyed US physicians’ recommended treatments for ICAS differed over
the 3 survey periods, reflecting the results of the 2 NIH-funded clinical trials of ICAS and
suggesting that these clinical trials changed practice in the US.
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INTRODUCTION
Intracranial atherosclerotic stenosis (ICAS) causes 8-10% of ischemic strokes in the US1
and is one of the most common causes of stroke worldwide2. Despite the high prevalence
and high risk of recurrent stroke associated with ICAS, optimal treatment for this disease is
still evolving. Over a decade ago, physician preferences regarding antithrombotic and
endovascular treatment of ICAS were largely based on retrospective studies3 and expert
opinion4, but since then, two large randomized trials have compared treatment strategies for
this disease. First, the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial
compared aspirin vs. warfarin among patients with symptomatic 50-99% intracranial
stenosis and found that aspirin was safer and as effective as warfarin for prevention of stroke
and vascular death in patients with ICAS5. More recently, the Stenting and Aggressive
Medical Management for Prevention of Recurrent stroke in Intracranial Stenosis
(SAMMPRIS) trial compared aggressive medical management vs. aggressive medical
management plus percutaneous transluminal angioplasty and stenting (PTAS) among
patients with symptomatic 70-99% stenosis and found a high rate of periprocedural stroke
after PTAS and a lower than expected rate of stroke on aggressive medical therapy6. The
impact of these large randomized trials on clinical practice has not been quantified.
Therefore, we sought to determine the impact of the results of these studies on treatment
choices of US physicians managing patients with ICAS by surveying physicians before and
after the publications of WASID and SAMMPRIS.
METHODS
Anonymous surveys of physician treatment choices were conducted at the following times:
1. Pre-WASID: prior to publication of WASID results (2004), 2. Post-WASID: 1 year after
publication of the WASID results (2006), and 3. Post-SAMMPRIS: approximately 1 year
after publication of the SAMMPRIS trial results (2012).
Pre-WASID Survey
The pre-WASID survey was conducted using a written questionnaire, sent by email or
conventional mail (if no email). The survey was sent to neurologists and included WASID
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investigators (n=90) and American Academy of Neurology (AAN) Stroke Section members
(n=435) and it was available for 8 weeks. One reminder was sent. Completed questionnaires
were faxed to the WASID Datafax server. The survey included 15 multiple choice questions
(Appendix A) on the following topics: physician's practice setting, experience treating
stroke, preferred antithrombotic agent for ICAS, willingness to change practice based on the
WASID results, current use of PTAS for ICAS.
Post-WASID Survey
The post-WASID survey was administered using an internet-based survey tool
(www.questionpro.com). The survey was sent to neurologists, including WASID
investigators and AAN Stroke Section members with available email addresses (n=233), and
neurointerventionists who were American Society of Interventional & Therapeutic
Neuroradiology (ASITN) members with available email addresses (n=365) and it was
available for 8 weeks. Not all email addresses were valid, but attempts were made to
ascertain the correct contact information and remove duplicates. Email notification of the
request to complete the survey and a link to the survey were sent and one reminder email
was sent.
The post-WASID survey included multiple choice questions (Appendix B) on the same
topics as the pre-WASID survey, but also included questions that asked respondents to
choose the maximum 2-year rate of stroke in the territory of the symptomatic intracranial
artery among patients treated with PTAS that would result in PTAS becoming their
treatment of choice for the following 2-year stroke rates on medical therapy: 25%, 20%,
16%, and 12%. The response options reflected a 25%, 33%, 40%, 50%, and 60% relative
risk reduction (RRR) from PTAS or “medical therapy would remain my treatment regardless
of stenting rate”.
Post-SAMMPRIS Survey
The post-SAMMPRIS survey was administered using the internet-based Research and
Electronic Data Capture (REDCap) survey tool7. The survey was sent to neurologists from
previous email lists and AAN Stroke Section members with available email addresses
(n=1400) and neurointerventionists from previous survey email lists and members of the
Society of Vascular Interventional Neurologist (SVIN) and Society of Neurointerventional
Surgeons (SNIS) (n=680) and it was available for one month. Attempts were made to
ascertain the correct contact information and remove duplicate emails. Email notification of
the request to complete the survey and a link to the survey were sent and one reminder email
was sent.
The post-SAMMPRIS survey included multiple choice questions (Appendix C) on the topics
of the prior surveys, but also included questions about the definition of “failure of medical
therapy”, factors that influence treatment with PTAS, and the impact of SAMMPRIS on
practice. Three questions asked respondents to choose the maximum 1-year rate of stroke in
the territory of the symptomatic intracranial artery among patients treated with a “new
endovascular procedure” that would result in that procedure becoming their treatment of
choice for the following 1-year stroke rates on aggressive medical therapy: 25%, 20%, and
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16%. The response options reflected a 25%, 33%, 40%, 50%, and 60% RRR from the “new
endovascular procedure” or “aggressive medical therapy would remain my treatment
regardless”.
Statistical Analysis
Responses were characterized by standard descriptive statistics (i.e. percentages). Survey
questions required categorical responses, with limited fields for ‘other’ answers. All
comparisons between groups were done using Chi-square analysis.
RESULTS
The overall response rates for the surveys were: pre-WASID, 34% (181/525); post-WASID,
33% (199/598), and post-SAMMPRIS, 15% (302/2080). While the target groups were
similar between the surveys, the number of respondents who completed more than one of the
surveys is unknown due to anonymity. As shown in Table 1, in all surveys, the majority of
respondents had University-based practices, were in practice 10 years or more, and at least
25% of their practice involved treating stroke patients. Respondents differed significantly in
practice type and years in practice since training, with more University-based respondents in
the post-WASID survey.
Medical Management
Willingness to change practice—In the pre-WASID survey, the majority of
neurologists (91%) indicated that if the 3-year stroke and vascular death rate was 30% on
their preferred antithrombotic treatment, they would require a 20-33% RRR from the more
effective antithrombotic agent to switch from their preferred agent, whether their preferred
agent was warfarin or aspirin. Only 3.6% would continue to use warfarin and 1.4% would
continue to use aspirin regardless of the WASID results.
Choice of antithrombotic medication—The neurologists’ preferred antithrombotic
agent differed significantly between pre-WASID and post-WASID surveys for the treatment
of both anterior circulation (p<0.001) and posterior circulation (p<0.001) stenoses. As
shown in Figure 1, the pre-WASID neurologists’ preferred antithrombotic treatment was
equally divided between warfarin and antiplatelet agents for anterior circulation stenosis, but
more neurologists preferred warfarin for posterior circulation stenosis. Compared to the
post-WASID respondents, more post-SAMMPRIS respondents preferred antiplatelet agents
for stenosis in the anterior circulation (85% vs. 94%, p=0.0017) and posterior circulation
(74% vs. 83%, p=0.0145).
Choice of antiplatelet agent—As shown in Table 2, the antiplatelet treatment most
commonly preferred for ICAS post-WASID was aspirin (44% for anterior circulation, 43%
for posterior circulation), whereas post-SAMMPRIS it was the combination of aspirin and
clopidogrel (45% for anterior circulation, 43% for posterior circulation). The preferred dose
of aspirin was 325 mg/day in both the post-WASID and post-SAMMPRIS surveys. The
dose of aspirin used in WASID (1300 mg/day) was preferred by only 11% of post-WASID
respondents and virtually no post-SAMMPRIS respondents. In the post-SAMMPRIS survey,
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the combination of aspirin and clopidogrel (which was used for 90 days after enrollment in
SAMMPRIS) was recommended for 30 days, 90 days, and indefinitely by 5%, 45%, and
44% of respondents, respectively.
Definition and treatment of patients on “maximal medical therapy”—In the post-
SAMMPRIS survey, the majority of respondents (61%) considered “maximal medical
therapy” to include both “use of antithrombotic treatment” and “use of aggressive medical
therapy to manage risk factors and achievement of SBP<140 and LDL<70”, which were the
risk factor targets in SAMMPRIS8. Only 4% of respondents considered “maximal medical
therapy” to include only “use of antithrombotic treatment”. For treatment recommendations
in patients with symptomatic intracranial stenosis who have “failed medical therapy”, 50%
of respondents reported that they “assess for compliance and/or intensity medical therapy”,
whereas 45% “recommend treatment with angioplasty or stenting”.
Endovascular treatment
Neurologist PTAS recommendations—The proportion of patients for whom the
neurologists recommended PTAS significantly increased from the pre-WASID to the post-
WASID survey (p<0.0001) and then decreased in the post-SAMMPRIS survey (p=0.0135)
to approximately pre-WASID levels, as shown in Figure 2. The majority of neurologists
recommended PTAS in less than 10% of their ICAS patients in all surveys.
Neurointerventionist PTAS recommendations—In the post-WASID survey, about
half of neurointerventionists (51%) reported that they recommended PTAS in 25% or less of
their patients with ICAS, but in the post-SAMMPRIS survey 84% recommended PTAS in
25% or less, as shown in Figure 2. The proportion of neurointerventionists who
recommended PTAS in over half of their patients with ICAS decreased from 29% post-
WASID to 9% post-SAMMPRIS.
Characteristics of patients selected for PTAS—In the post-SAMMPRIS survey, the
patient characteristics that were most commonly selected as influencing the decision to
recommend PTAS were: symptoms attributed to hypoperfusion (81%), severe stenosis
(68%), impaired collaterals (59%), and recent symptoms (54%).
Required risk-reductions to change treatment of choice—Figure 3 shows the
percentage of respondents in the post-WASID and post-SAMMPRIS surveys who selected
each RRR for PTAS (post-WASID) or a “new endovascular procedure” (post-SAMMPRIS)
for the proposed 2-year rates of stroke in the territory of the symptomatic stenotic artery on
medical treatment. For a stroke rate of 25% on medical therapy, the majority of post-
WASID respondents required a minimum RRR of 33% (corresponding to a number needed
to treat (NNT) of 13) from PTAS to make PTAS their treatment of choice. As the stroke rate
on medical therapy decreased, the RRR required increased. In the post-SAMMPRIS survey,
the majority of respondents wanted a RRR of 40% (NNT of 10 for a stroke rate of 25% on
medical therapy) from the “new procedure”, which is a higher RRR compared to the post-
WASID survey respondents for the same event rate of 25% on medical therapy. For a
medical therapy stroke rate of 16%, the majority of post-WASID respondents required a
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minimum RRR of 40% (NNT of 17) from PTAS to make PTAS their treatment of choice. In
the post-SAMMPRIS survey, the majority of respondents wanted a RRR of 50% (NNT of
13 for a stroke rate of 16% on medical therapy) from the “new procedure”, which is also a
higher RRR compared to the post-WASID survey respondents for the same event rate of
16% on medical therapy.
Impact on practice—In the Post-SAMMPRIS survey, 91% (100/110) of respondents who
participated in SAMMPRIS and 82% (228/277) of overall respondents indicated that the
SAMMPRIS results changed the way they managed patients with ICAS.
DISCUSSION
Previous surveys have examined stroke prevention practices9-11, but our surveys focused on
the impact of two large randomized clinical trials on physician treatment practices for ICAS
in the US. We found significant differences in treatment choices for both medical and
endovascular treatment of ICAS across the 3 surveys. While we found a tendency to adopt
both medical and endovascular treatments supported by the clinical trial results, not all of
the more effective treatment strategies in the trials were widely adopted.
Medical management of ICAS changed over the three study periods, which extended over
more than a decade. After the publication of the WASID results, most neurologists preferred
antiplatelet therapy over warfarin, and the preferred antiplatelet agent in the post-WASID
survey was aspirin. However, despite the fact that aspirin was the only antiplatelet agent
tested in WASID, a surprising number of respondents in the post-WASID survey (more than
half) preferred other antiplatelet agents or combinations of antiplatelet agents over aspirin.
This finding may be due to studies that showed other antiplatelet regimens may have a role
in preventing stroke in patients with large artery atherosclerosis12, 13. The most commonly
prescribed dose of aspirin in the post-WASID survey was 325 mg/day, despite the fact that
the dose used in WASID was 1300 mg/day14. A stroke prevention guideline statement
published around the time of the post-WASID survey (2006) recommended aspirin doses of
50-325 mg/day in patients with atherosclerotic stroke or TIA based on general safety and
efficacy data15, suggesting that our survey results regarding aspirin dose are consistent with
consensus expert opinion at the time.
The neurologists’ preference for dual antiplatelet (aspirin and clopidogrel) therapy in
patients with ICAS increased from the post-WASID to the post-SAMMPRIS surveys. This
is likely because of the lower early recurrent stroke rates in SAMMPRIS (when patients
were on a combination of aspirin and clopidogrel) compared to WASID historical controls
taking either aspirin or warfarin6. Results from the CLAIR study also that showed combined
aspirin and clopidogrel decreased the number of microembolic signals on transcranial
doppler compared to aspirin alone in patients with recently symptomatic ICAS 16, further
supporting the use of dual antiplatelet therapy for early recurrent stroke prevention in ICAS.
However, despite the fact that in the SAMMPRIS trial dual antiplatelet therapy was only
used for 90 days, almost equal numbers of respondents in the post-SAMMPRIS survey
recommended dual antiplatelet therapy for 90 days (45%) and indefinitely (44%). So, in
both the post-WASID and post-SAMMPRIS surveys it appears that the general selection of
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anti-thrombotic agents may be influenced by the clinical trial results, but that the specifics of
the trial treatment protocols (e.g. specific antiplatelet agent or duration of treatment) were
not strictly adopted.
The post-SAMMPRIS survey respondents’ definitions of “maximal medical management”
included risk factor modification as a component, with only 4% of respondents indicating
that “failure of medical therapy” was limited to failure of antithrombotic agents alone. This
finding probably reflects the respondents’ recognition of the benefit of intensive risk factor
management for improving the outcomes in medically treated patients in the SAMMPRIS
trial compared to WASID historical controls6 as well as previous analyses of WASID and
SAMMPRIS data that have demonstrated that ‘failure of antithrombotic therapy’ is not a
useful predictor of increased risk of recurrent stroke in patients with ICAS17, 18.
While the majority of neurologists recommend PTAS in < 10% of their patients with ICAS
in all survey periods, the percentage of neurologists who recommended PTAS in > 10% of
patients significantly increased from the pre- to the post-WASID surveys. This finding is
consistent with a retrospective study that showed an increase in intracranial PTAS
procedures after the publication of the WASID results19. The increased frequency of
endovascular procedures for ICAS after WASID, despite lack of evidence for their efficacy
for stroke prevention, may have reflected a perceived failure of medical therapies given the
high risk of recurrent stroke in WASID and the availability of the Wingspan stenting system
that was approved by the FDA under a humanitarian device exemption (August 3, 2005).
However, in the post-SAMMPRIS survey, the percentage of neurologists who recommended
PTAS in > 10% of patients returned to pre-WASID levels, likely due to the early
SAMMPRIS results that showed no benefit from PTAS6.
The post-WASID and post-SAMMPRIS surveys asked respondents what benefit they would
require from endovascular procedures (PTAS and a “new endovascular procedure”,
respectively) over medical therapy to make the procedure their treatment of choice for
ICAS. For carotid stenosis, the North American Symptomatic Carotid Endarterectomy Trial
(NASCET)20 showed the 2-year risk of ipsilateral stroke in patients with symptomatic
extracranial carotid stenosis was 26% on medical therapy and 9% with surgical therapy,
resulting in a NNT with endarterectomy of 6 patients. In our survey of ICAS treatment
preferences, for a risk of stroke on medical therapy similar to NASCET (25% at 2-years),
the majority of our respondents required a NNT of 13 patients to make an endovascular
procedure the treatment of choice over medical therapy. This finding suggests that
physicians may incorporate the risk/benefit ratio of established stroke prevention
interventions into their expected benefits of procedures or they may have an inherent
threshold for benefit that they feel is optimal for similar high-risk conditions. As expected,
the RRR from PTAS and the “new endovascular procedure” required by our survey
respondents increased as the proposed risk of stroke on medical therapy decreased. In other
words, as the rates of recurrent stroke with medical therapy decrease, the respondents
require a much larger benefit from ICAS endovascular procedures to make the procedures
their treatment of choice.
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One of the reasons we undertook the post-WASID survey was to help design the “Stenting
and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial
Stenosis (SAMMPRIS)” Trial21. Historically, the hypothesized benefit of one treatment over
another in many trials has been selected by estimating the treatment effect that physicians
and patients would deem important to adopt a new treatment and by considering the
feasibility of recruiting the required sample size. We chose to quantify the minimum benefit
from PTAS that would make it the treatment of choice by surveying physicians who take
care of patients with ICAS. The use of physician surveys may provide a more scientific
approach for determining the clinically meaningful benefit that physicians will require to
adopt a new treatment, thereby increasing the impact of clinical trials on clinical practice.
Our study has some weaknesses, including the practice type and experience differences
between the pre- and post-WASID survey respondents. The post-WASID survey included
more University-based respondents than the other surveys, but the majority of respondents
were at University centers in all 3 surveys. Additionally, we did not survey a random sample
of physicians who take care of patients with ICAS and we limited the survey to physicians
in the US. Given that the approach to patients with intracranial stenosis varies in different
countries such as China22, our results may not be representative of physicians who treat
patients with ICAS worldwide. Finally, our survey data are self-reported and therefore
subject to the inherent biases of such data, such as social desirability bias and recall bias.
In summary, our study shows that after the publications of the NIH-funded WASID and
SAMMPRIS trials, there was a significant change in physician self-reported medical and
endovascular treatment practices for ICAS in the US. Based on these results, we expect that
future clinical trials to determine the best management of patients with ICAS will likely
have a significant impact on physician practices.
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Appendix C: Intracranial Stenosis Treatment Post-SAMMPRIS
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Antithrombotic medication treatment preferences for symptomatic intracranial stenosis is 3
surveys
Turan et al. Page 16























Percentage of respondents who recommend angioplasty and stenting for a given proportion
of patients with ICAS
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Relative Risk Reduction (RRR) required by respondents to make the endovascular
procedure the treatment of choice over medical therapy
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